Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (GB:0HFQ)
LSE:0HFQ
Holding GB:0HFQ?
Track your performance easily
0HFQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.80 - $41.25
Previous Close$32.08
Volume11.00
Average Volume (3M)297.00
Market Cap
$976.96M
Enterprise Value$643.11M
Total Cash (Recent Filing)$350.80M
Total Debt (Recent Filing)$16.95M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Nov 07, 2024EPS Estimate
-$1.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding30,184,531
10 Day Avg. Volume214
30 Day Avg. Volume297
Standard Deviation0.21
R-Squared0.00477
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)101.36
Price to Sales (P/S)32.04
Price to Cash Flow (P/CF)-11.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue21.10
Enterprise Value/Gross Profit37.48
Enterprise Value/Ebitda-4.10
Forecast
1Y Price Target
$54.33Price Target Upside69.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
AnaptysBio News
Bulls Say, Bears Say
Bulls Say
Drug Development PotentialManagement highlighted the company’s vision for its BTLA agonist (ANB032) to address AD beyond the Th2 cell-mediated pathway and its optimism about the Ph2 topline readout.
Financial Strength And GrowthShares have increased by 52% YTD, and the stock is expected to continue moving up preceding upcoming events, showcasing strong market performance and growth potential.
Strategic InvestmentANAB announced a $100M direct offering, including participation from SAN FP, which indicates confidence from significant investors and potential interest in future partnerships.
Bears Say
Competitor DevelopmentsCompetitor LLY's updates on their PD-1 agonist, peresolimab, could negatively impact ANAB if LLY progresses with their drug.
Financial PerformanceThe company reported a net loss of $46.7M, which is significantly higher than both the estimate of $41.6M and the consensus of $22.1M.
Program TerminationFirst generation BTLA agonists, including LY3361367 and AVTX-008, have been terminated, impacting programs focused on conditions like SLE.
---
Options Prices
Currently, No data available
---
Ownership Overview
43.61% Insiders
18.97% Mutual Funds
0.03% Other Institutional Investors
26.56% Public Companies and
Individual Investors
0HFQ FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest share price was $13.80 and its highest was $41.25 in the past 12 months.
What is AnaptysBio Inc’s market cap?
Currently, no data Available
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Nov 07, 2024 which is in 28 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Aug 05, 2024. The company reported -$1.71 earnings per share for the quarter, missing the consensus estimate of -$1.041 by -$0.669.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -$1.7.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 30,199,814 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.71 in its last earnings report, missing expectations of -$1.041. Following the earnings report the stock price went up 3.784%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Among the largest hedge funds holding AnaptysBio Inc’s share is Woodline Partners LP. It holds AnaptysBio Inc’s shares valued at 6M.
---
AnaptysBio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.33 (69.37% Upside)
$54.33 (69.37% Upside)
Blogger Sentiment
Bullish
GB:0HFQ Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $10.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.54%
12-Months-Change
Fundamentals
Return on Equity
-214.89%
Trailing 12-Months
Asset Growth
-17.35%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
---
0HFQ Stock 12 Month Forecast
Average Price Target
$54.33
▲(69.37% Upside)
Technical Analysis
Best Analysts Covering 0HFQ
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
-26.96%
reiterated a buy rating 15 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of -26.96% per trade.
---